CALA News and Press, Calithera Biosciences Inc. From 05/29/20

KEAPSAKE is a planned Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinic...

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced ...

"Everything at some point has been declared the root of all evil ." - Criss Jami Today, we revisit a Tier 4 biotech concern that continues to advance its pipeline and one we have not looked at in some time. Its stock has held up well in the volatility in the market in 2020. The company ...

Calithera Biosciences, Inc. (CALA) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Corporate Participants Jennifer McNealey - Investor Relations Susan Molineaux - Founder, President and CEO Keith Orford - Chief Medical Officer Stephanie Wong - Senior Vice President o...

Image source: The Motley Fool. Calithera Biosciences Inc   (NASDAQ: CALA) Q1 2020 Earnings Call May 7, 2020 , 5:00 p.m. ET Operator Continue reading

SOUTH SAN FRANCISCO, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today annou...

SOUTH SAN FRANCISCO, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announce...

Gainers: MoSys (NASDAQ: MOSY ) +100% . More news on: MoSys, Inc., Liberty TripAdvisor Holdings, Inc., Arcus Biosciences, Inc., Stocks on the move, , Read more ...

Diamond Offshore Drilling (NYSE: DO )  -35%  after skipping interest payment. More news on: Diamond Offshore Drilling, Inc., Athersys, Inc., InVivo Therapeutics Holdings Corp., Stocks on the move, , Read more ...

Calithera Biosciences (NASDAQ: CALA ) prices its public offering and sells 5M common shares at $6.25/share, for expected gross proceeds of $31.25M. More news on: Calithera Biosciences, Inc., Healthcare stocks news, , Stocks on the move, Read more ...